Background Chemotherapy is a partially effective treatment for advanced non-small-cell
lung cancer (NSCLC), the leading cause of cancer mortality in the US. The epidermal …

Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …

Subsets of patients with non-small cell lung cancer (NSCLC) who carry somatic mutations in
the epidermal growth factor receptor (EGFR) have responded remarkably well to a tyrosine …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …

Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in
specimens from patients with non–small-cell lung cancer who have a response to …

Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …

Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …

Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …